Renal dysfunction is one of the most prevalent complications of uncontrolled type 2 DM, especially when proteinuria and obesity are present. Dapagliflozin affects the kidneys by increasing the quantity of sugar eliminated via the urine. In type 2 diabetes patients, SGLT2 inhibitors minimise renal glucose reabsorption and enhance glycemic control.